Senior Advisor Life Science Financing and President HealthiosXchange – healthcare focused capital raising and investor portal

Healthios – Consultant
S. Jordan Associates
2010 – Present (3 years)Greater Chicago Area
Manage biopharmaceutical M&A, private placement, business development/licensing, and strategic advisory engagements for Healthios, a life sciences investment bank. Draft documents (management presentations, offering memorandums), prepare financial models, lead client interactions/marketing, conduct due diligence, and structure and negotiate transactions.

Healthios and SJA launching HealthiosXchange (H/X), the premier healthcare Crowdfunding Portal including Equity/Reg D (Crowd Finance, Ex.PR.E.S.S,) Venture Philanthropy (Foundation Place), and OTC.BB/Direct listing./At the Market (InMarket) Crowdfunding Portals

Bringing institutional and Accredited investors together with 50,000 emerging growth healthcare companies, inspiring new investment and financing alternatives in a dynamic, real-time and transparent transaction environment.

Crowd Finance Portal – Online platform for early-stage, non venture-backed healthcare companies to raise capital from Accredited investors via Special Purpose Vehicles (SPV’s) allowing investors to diversify investments across a broad range of companies/therapeutic sectors (lower investment thresholds).

Ex.PR.E.S.S Portal. – “Fee Free”, “Carry Free” co-investments alongside top-tier institutional investors and the most important strategic buyers

Foundation Place – Partnering with prominent mission-based organizations to advance the success of the most vital human priorities

Liquid iT – A secondary transaction environment committed to generating liquidity for investors by making markets in a range of asset classes

InMarket – Harnessing the public markets to inspire transformational growth strategies via OTC.BB, Reverse Mergers, “At the Market,” and Syndicated Direct financing platforms.

NeoPharm – Developed strong relationships with Japanese Biopharma companies including Nippon Kayaku, Taiho, Sumitomo Corporation, Daiichi Sankyo, Eisai, Chugai Biopharmaceuticals, Kissei, Kyowa Hakko-Kirin, and Astellas Pharma. Signed a licensing agreement with Nippon Kayaku, a leading Japanese pharmaceutical company with over $1.2 billion in revenues for the rights to IL13-PE38QQR (Glioblastoma Multiforme) on December 28, 2004. NeoPharm received a $3 million upfront payment with potential milestones of $25 million.

Negotiated a research/material transfer agreement with Wyeth-Ayerst resulting in a multi-million offer to license NeoPharm’s Phase I antisense compound, LErafAON, in 2002

Signed marketing/distribution rights to NeoPharm’s proprietary cardiolipin based transfection agents, NeoPhectin and NeoPhectin (AT), with Nippon Genetics, Inc. and Avanti Polar Lipids

Assisted NeoPharm CEO with secondary offering of 4.3 million shares at $18.25 per share, underwritten by UBS Warburg and priced on 1/21/04 (raised $74 million in net proceeds)

Akorn Opthalmics – Built and managed a national sales team and new product launches (Visoelastic, Dry Eye Test)

Specialties:Corporate Finance – Capital formation through retail and institutional investors: Venture Capital, broker/dealers, Angels, family offices, accredited investors, Crowdfunding

Investment Vehicles: Private placements/Reg D offerings, Direct Listings, PIPES and Equity Crowdfunding – method of raising capital in small amounts from a large group of people using the Internet.

Business Development: Licensing/Partnerships, Joint Ventures

Coordinate/Manage Industry Partnering Forums: H/X @ ASCO 2012